NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir
November 29, 2021 06:31 ET
|
NRx Pharmaceuticals, Inc.
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study...
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research
November 26, 2021 10:06 ET
|
NRx Pharmaceuticals, Inc.
Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original...
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
November 16, 2021 05:56 ET
|
NRx Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the...
NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference
November 12, 2021 11:46 ET
|
NRx Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer,...
NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing Information
November 11, 2021 07:54 ET
|
NRx Pharmaceuticals, Inc.
US Food and Drug Administration Review Allows for High Volume Production of ZYESAMI® (aviptadil)Shelf Life of ZYESAMI Now Extended from 62 Days to 150 Days RADNOR, Pa., Nov. 11, 2021 (GLOBE...
NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021
November 09, 2021 12:32 ET
|
NRx Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical-stage, global biopharmaceutical company, today announced that management will report third-quarter...
UPDATE: NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)
March 19, 2021 17:28 ET
|
NeuroRx, Inc.
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
NeuroRx to Present at the Annual Rodman & Renshaw Global Investment Conference on Sept 5, 2018
September 05, 2018 08:00 ET
|
NeuroRx, Inc.
WILMINGTON, Del., Sept. 05, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation...
NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)
September 04, 2018 09:10 ET
|
NeuroRx, Inc.
WILMINGTON, De. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation...
NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation & Behavior
May 07, 2018 07:00 ET
|
NeuroRx, Inc.
WILMINGTON, Del., May 07, 2018 (GLOBE NEWSWIRE) -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute...